Merck to Acquire Idenix Pharma for $3.85B

Jun 09, 2014

The New York Times

According to a New York Times article, Merck will buy the biotechnology company Idenix Pharmaceuticals for $3.85 billion in an effort to bolster its arsenal of potential drugs in the hotly competitive hepatitis C area, the companies announced on Monday.

“Idenix has established a promising portfolio of hepatitis C candidates,’’ Dr. Roger Perlmutter, the president of Merck Research Laboratories, said in a statement Monday. He said those candidates would help Merck develop what is considered an ideal regimen – taken once a day for as short a duration as possible and highly effective against all subtypes of the hepatitis C virus. Read the full story

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments